Mainz Biomed is thrilled to announce exciting new partnerships with Marylebone Lab LTD and Instituto de Microecologia, two leading independent laboratories covering England and Spain respectively. Through this collaboration, Mainz Biomed’s flagship product, ColoAlert, will be commercially available to detect the early signs of colorectal cancer (CRC). ColoAlert is a highly efficacious and easy-to-use, at-home detection test that is revolutionizing the traditional methodology of operating a single facility for test kit processing. With this innovative business model, Mainz Biomed is now making ColoAlert available across Europe and in select international markets.
Mainz Biomed is proud to announce the addition of Marylebone Lab and Instituto de Microecologia to its network of laboratory partners. We are committed to providing premier diagnostic tests to support the early detection of deadly diseases such as colorectal cancer, the second most lethal cancer in Europe. By aligning with top laboratories, we hope to make a dramatic impact on treatment and prevention and ultimately save lives.
Mainz Biomed is set to launch ColoAlert in Spain and the greater London region, with a total of 26 million and 9 million patients respectively. The company is currently finalizing the technical and co-marketing activities with their partners Marylebone and Instituto de Microecologia, to ensure a successful launch in these markets. With this move, Mainz Biomed is poised to make a powerful impact on the healthcare industry.
About ColoAlert
ColoAlert is a revolutionary new way to detect colorectal cancer (CRC) in its early stages. This simple-to-administer test utilizes proprietary methods to analyze cell DNA for specific tumor markers combined with the fecal immunochemical test (FIT). Commercially available in a selection of countries in the European Union and the United Arab Emirates, the product is also CE-IVDR marked, ensuring it meets the highest safety, health and environmental requirements. With plans to expand into the US, Mainz Biomed is currently establishing a scalable distribution network through a collaborative partner program with regional and national laboratory service providers.
About Colorectal Cancer
Colorectal cancer (CRC) is the second deadliest cancer in the US and Europe, but also the most preventable with early detection. The American Cancer Society estimated that in 2021, 149,500 new cases of colon and rectal cancer were reported in the US, with 52,980 resulting in death. The US Food and Drug Administration (FDA) has recently approved the use of stool DNA tests such as ColoAlert for screening, which should now be conducted on all individuals aged 45 and over every three years. This could mean a potential market opportunity of $3.7 billion per year, as the number of people aged 50 and over in the US is expected to grow to 157 million in the next decade.
About Mainz Biomed NV
Mainz Biomed is revolutionizing the world of molecular genetic diagnostics with life-saving solutions such as ColoAlert, an accurate, non-invasive and easy-to-use early-detection diagnostic test for colorectal cancer. ColoAlert is already market-ready and is currently being sold in Europe and the United Arab Emirates. The Company is currently running a pivotal FDA clinical study for US regulatory approval and is also developing PancAlert, a revolutionary early-stage pancreatic cancer screening test based on real-time PCR multiplex detection of molecular-genetic biomarkers in stool samples.